Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Dement Geriatr Cogn Disord. 2007;24(2):118-24. Epub 2007 Jul 2.

Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly.

Author information

  • 1Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, University Hospital MAS, Malmo, Sweden. erik.stomrud@med.lu.se

Abstract

OBJECTIVE:

To investigate whether cerebrospinal fluid (CSF) biomarkers can predict cognitive decline in healthy, elderly individuals as they have been shown to do in cognitively impaired patient samples.

METHODS:

In this study, 57 controls were tested for CSF biomarkers at baseline and then cognitively followed over 3 years.

RESULTS:

Low levels of baseline beta-amyloid 1-42 (Abeta42) were associated with development of subjective memory impairment affecting quality of life (memQoL), with a worse Mini Mental Status Examination score and with inability to live in regular housing at follow-up (p < 0.05). The combination of baseline Abeta42 and phosphorylated tau (P-tau) was found to predict development of pathological memQoL with a sensitivity of 71.4% and a specificity of 75.7 (<0.01).

CONCLUSION:

Low Abeta42 and combined Abeta42 and P-tau predicted subjective cognitive decline in healthy individuals. In summary, this study shows that already in the clinically normal population Alzheimer-disease-related biological signs might be detectable.

(c) 2007 S. Karger AG, Basel.

PMID:
17622715
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Write to the Help Desk